Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban plus aspirin vs aspirin alone for prevention of early neurological deterioration in acute ischemic stroke
ChiCTR2500110858Phase 4Not yet recruiting
- Sponsor
- Shantou Central Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of argatroban in ischemic stroke (2 arms), sponsored by Shantou Central Hospital. Primary endpoint: Early neurological deterioration within 7 days. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
argatroban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500110858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110858.